Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone, Rosa Lerose

Research output: Contribution to journalArticlepeer-review

Abstract

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.

Original languageEnglish
Pages (from-to)242-250
Number of pages9
JournalTherapeutic Advances in Respiratory Disease
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 29 2015

Keywords

  • AZD9291
  • CO-1686
  • epidermal growth factor receptor activating mutations
  • HM61713
  • non-small cell lung cancer
  • T790M mutation
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance'. Together they form a unique fingerprint.

Cite this